Holocene Advisors
KZR

Holocene Advisors’s Kezar Life Sciences KZR Stock Holding History

Holocene Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-157,305
Closed -$13.9M – 916
2022
Q1 		$26.1M Buy
157,305
+57,080
+57% +$8.19M 0.14% 169
2021
Q4 		$16.8M Buy
+100,225
New +$11.3M 0.09% 205

Other funds holding KZR

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Holocene Advisors's KZR Position: Q2 2022 in Review

Holocene Advisors sold out of Kezar Life Sciences (KZR) in Q2 2022, closing a stake of 157,305 shares — an estimated $13.9M sold.

Holocene Advisors first reported a position in KZR in Q4 2021 and held it in 2 quarters. The position peaked at $26.1M in Q1 2022. 127 funds tracked by Wall St. Rank hold KZR as of Q2 2022.

  • Holocene Advisors reported no remaining Kezar Life Sciences position as of Q2 2022 after selling out during the quarter.
  • Holocene Advisors sold 157,305 Kezar Life Sciences shares in Q2 2022, an estimated $13.9M.
  • Holocene Advisors first reported a position in Kezar Life Sciences in Q4 2021 and held it in 2 quarters.
  • Holocene Advisors's Kezar Life Sciences position peaked at $26.1M in Q1 2022.
  • 127 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2022.

Based on Holocene Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.